Skip to content
2000
Volume 20, Issue 20
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Inflammation has recently been implicated as a critical mechanism in Alzheimer’s disease (AD). Microglia are the resident immune cells in the central nervous system (CNS), and they mediate the inflammatory response in the AD brain. Thus, suppression of microglial activation and subsequent neuroinflammation may be a potential therapeutic approach against AD. In the following review, we briefly discuss the limitations and advantages of current drug targets for AD and then summarize several anti-inflammatory drugs in trial, including natural nonsteroidal anti-inflammatory drugs (NSAIDs), polyphenols and new drugs synthesized based on multi-target directed ligand (MTDL) design. In addition to their anti-inflammatory effects, these drugs can act as anti-oxidants and reduce microglial activation or amyloid-β (Aβ) plaques. Thus, the studies focused on multiple factors in AD processes might reveal the best potential treatment strategy for the future.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867311320200006
2013-07-01
2025-05-09
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867311320200006
Loading

  • Article Type:
    Research Article
Keyword(s): Alzheimer’s disease; anti-inflammatory drugs; microglia; MTDL; NSAIDs; polyphenols
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test